8-K: Humana Raises Full-Year Adjusted EPS and Revenue Guidance Amidst Shifting Medicare Advantage Landscape

Humana reported solid second-quarter 2025 financial results, raising its full-year adjusted earnings per share and consolidated revenue guidance, despite a revised outlook for individual Medicare Advantage membership decline.

Summary

• Reported Second Quarter 2025 GAAP EPS of $4.51 and Adjusted EPS of $6.27.
• Year-to-date GAAP EPS was $14.81 and Adjusted EPS was $17.85.
• The Insurance segment benefit ratio for Q2 2025 was 89.9%, aligning with the company's expectation of 'approximately 90 percent'.
• Full-year 2025 GAAP EPS guidance was updated to 'approximately $13.77' from the previous 'approximately $14.68'.
• Full-year 2025 Adjusted EPS guidance was raised to 'approximately $17.00' from 'approximately $16.25'.
• Full-year 2025 consolidated revenues guidance was raised to 'at least $128 billion' from the previous range of $126 billion to $128 billion.
• The FY 2025 Insurance segment benefit ratio guidance range of 90.1% to 90.5% was affirmed.
• Individual Medicare Advantage membership guidance was revised to anticipate a decline of 'up to 500,000 members' for FY 2025, an improvement from the previous guidance of 'approximately 550,000'.
• CenterWell Primary Care now anticipates FY 2025 net patient growth of 50,000 to 70,000, exceeding the previously expected range of 30,000 to 50,000.
• CenterWell Home Health (CWHH) same store admissions guidance was reduced to a low single-digit percentage increase for FY 2025, down from a previous expectation of mid to high single-digit growth.
• Debt-to-total capitalization decreased to 40.7% at June 30, 2025, from 42.8% at March 31, 2025.
• Days in claims payable (DCP) decreased to 36.5 days at June 30, 2025, from 41.6 days at June 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While GAAP EPS guidance was lowered and Medicare Advantage membership is still declining, the company raised its Adjusted EPS and revenue guidance, indicating strong operational performance and effective management of key business segments like CenterWell. The strategic initiatives and improved membership outlook for MA, despite the overall decline, suggest a resilient business model adapting to market challenges.

Positives

• Raised full-year 2025 Adjusted EPS guidance to approximately $17.00, up from $16.25.
• Increased full-year 2025 consolidated revenues guidance to at least $128 billion, exceeding the prior range.
• Individual Medicare Advantage membership decline is now anticipated to be 'up to 500,000 members', an improvement from the previous 'approximately 550,000' decline.
• CenterWell Primary Care's FY 2025 net patient growth guidance increased to 50,000 to 70,000, reflecting 15% growth at the midpoint, ahead of prior expectations.
• CenterWell Pharmacy outperformed expectations due to higher script volumes and favorable drug mix.
• CenterWell Pharmacy recently gained access to 17 new limited distribution drugs and won the MMIT Patient Choice award for the 7th time in 8 years.
• Launched Virginia Medicaid contract in July, creating a new dual special needs plan (D-SNP) market growth opportunity.
• Secured recent group wins for 2026 in Group Medicare Advantage, including the Teacher Retirement System of Kentucky and the Alabama Public Education Employees' Health Insurance Plan.
• Debt-to-total capitalization improved to 40.7% from 42.8% in the prior quarter, driven by debt repayment and Q2 earnings.
• Days in claims payable (DCP) decreased to 36.5 days, indicating faster claims processing, primarily due to structural changes from the Inflation Reduction Act.

Negatives

• Full-year 2025 GAAP EPS guidance was lowered to approximately $13.77 from $14.68.
• Second Quarter 2025 GAAP EPS of $4.51 was lower than $5.62 in Q2 2024.
• Second Quarter 2025 Adjusted EPS of $6.27 was lower than $6.96 in Q2 2024.
• Individual Medicare Advantage membership is still expected to decline by up to 500,000 members in FY 2025, largely due to exiting certain unprofitable plans and counties.
• CenterWell Home Health (CWHH) same store admissions growth guidance was reduced to a low single-digit percentage increase for FY 2025, down from mid to high single-digit growth.
• The number of Medicare Advantage plans rated 4-star or higher will significantly decline in 2025, potentially negatively impacting 2026 quality bonus payments from CMS, revenues, operating results, and cash flows.
• Operating cash flows for YTD 2025 remained relatively unchanged from YTD 2024, reflecting unfavorable working capital items partially offset by higher earnings.

Risks

• Inability to properly design and price products, insufficient premiums, or inadequate estimates of benefits expense could materially adversely affect profitability.
• Failure to effectively implement operational and strategic initiatives, particularly Medicare initiatives, state-based contract strategy, CenterWell business growth, and integrated care delivery model, could materially adversely affect the business.
• The significant decline in 2025 Medicare Advantage plans rated 4-star or higher, and the potential failure of a lawsuit to set aside these ratings, could negatively impact 2026 quality bonus payments, revenues, operating results, and cash flows.
• Failure to maintain data integrity, strategically maintain or implement new information systems, protect proprietary rights, or defend against cybersecurity attacks or privacy incidents could materially adversely affect the business.
• Involvement in various legal actions, disputes, governmental and internal investigations could result in substantial monetary damages or changes in business practices, increasing the cost of doing business.
• As a government contractor, exposure to risks such as loss of material government contracts, governmental audits and investigations, potential inadequacy of government-determined payment rates, and restrictions on profitability.
• Changes to the risk-adjustment model utilized by CMS, or retrospective recovery of previously paid premiums due to the Final RADV Rule, could have a material adverse effect on operating results, financial position, and cash flows.
• Substantial government regulation, new laws or regulations, or changes in existing laws or their application could increase costs and materially adversely affect results of operations, financial position, and cash flows.
• Failure to successfully manage acquisitions, divestitures, and other significant transactions may have a material adverse effect on results of operations, financial position, and cash flows.
• Failure to develop and maintain satisfactory relationships with care providers could adversely affect the business.
• Significant competition in attracting and retaining talented employees, and failure to manage succession for and retention of key executives, could adversely affect businesses, operating results, and/or future performance.
• The pharmacy business is highly competitive and subject to regulations and supply chain risks, and changes in prescription drug industry pricing benchmarks may adversely affect financial performance.
• Ability to obtain funds from certain licensed subsidiaries is restricted by state insurance regulations.
• Downgrades in debt ratings, if they occur, may adversely affect business, results of operations, and financial condition.
• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of the investment portfolio and investment income.

Future Outlook

Humana anticipates full-year 2025 Adjusted EPS of approximately $17.00 and consolidated revenues of at least $128 billion. The company expects a decline of up to 500,000 individual Medicare Advantage members for the full year, an improvement from prior estimates. CenterWell Primary Care is projected to achieve net patient growth of 50,000 to 70,000 in FY 2025. The company remains confident in its 2025 Medicare Advantage pricing strategy to drive underlying margin improvement and is focused on strengthening its Stars program for future years. Third-quarter earnings are expected to be approximately 15% to 20% of full-year Adjusted earnings, with the Insurance segment benefit ratio just above 91%. The company maintains a conservative assumption for the Doc Fix in 2025 and aims for a long-term debt-to-capitalization ratio of approximately 40%.

Management Comments

• "We feel good about our solid performance in the first half of the year. It reinforces our strategy to continue investing in improved outcomes, operational excellence and a better experience for our customers and investors." Jim Rechtin, President and CEO
• "We continue to expect the FY 2025 Insurance segment benefit ratio to be in a range of 90.1% to 90.5%."
• "Updated FY 2025 Adjusted EPS guidance now contemplates an additional approximately $100 million of incremental investments to improve member and patient outcomes and support operational excellence, positioning the company for long-term success."
• "Remains confident in 2025 pricing strategy as the company prioritizes benefit structure that is expected to drive sustainable, long-term value creation."
• "Committed to achieving individual MA pretax margin of at least 3% over time."
• "Efforts to strengthen our Stars program are progressing as anticipated with initiatives expected to have impact across key measures as we focus on achieving Top Quartile Stars results."
• "Medicaid continues to execute in line with expectations YTD."
• "CenterWell is driving strong results YTD and we continue to strategically expand our footprint."
• "Looking ahead, we remain focused on delivering a more stable and compelling MA margin by delivering clinical excellence for our members and patients through levers that are within our control."
• "We have conviction that the strong core fundamentals and growth outlook for MA and value-based care remain intact and that Humanas platform, unique focus on MA, and expanding CenterWell and Medicaid capabilities will allow us to compete effective, drive better outcomes for our members and patients, and deliver compelling shareholder value over the long term."

Industry Context

Humana's results reflect the ongoing dynamics in the U.S. healthcare industry, particularly within Medicare Advantage (MA) and Medicaid. The company is navigating changes related to the Inflation Reduction Act (IRA) and CMS risk adjustment models, which are impacting revenue and benefit ratios across the sector. The strategic expansion of its CenterWell primary care and pharmacy services aligns with a broader industry trend towards integrated care delivery and value-based care models, aiming to improve patient outcomes and manage costs. The focus on improving MA margins and Stars ratings is critical in a highly competitive and regulated market where quality and efficiency directly impact reimbursement and member retention. The company's efforts to manage membership declines in certain MA plans by exiting unprofitable areas and recapturing members into other plans demonstrate a strategic response to market pressures and a focus on profitability over sheer volume.

Comparison to Industry Standards

• The Medicare Advantage market is highly competitive, with major players like UnitedHealth Group (Optum), CVS Health (Aetna), and Elevance Health (Anthem) also vying for market share and navigating regulatory changes. Humana's revised individual MA membership decline of 'up to 500,000' for FY 2025, while still a decline, is an improvement from its previous guidance, suggesting a more effective mitigation strategy compared to initial expectations.
• The affirmed FY 2025 Insurance segment benefit ratio guidance of 90.1% to 90.5% indicates a managed approach to medical costs, which is a key metric for health insurers. This range should be assessed against peers' benefit ratios to determine relative efficiency in managing healthcare expenses.
• Humana's strategic expansion of CenterWell Primary Care, with anticipated FY 2025 net patient growth of 50,000 to 70,000, reflects a strong commitment to value-based care. This growth rate, particularly the 15% at the midpoint, is robust and compares favorably to the organic growth rates of primary care clinics operated by other integrated health systems or standalone value-based care providers.
• The decline in 2025 Medicare Advantage Star Ratings for Humana's plans is a significant headwind, impacting 2026 quality bonus payments. This contrasts with some competitors who may have maintained or improved their Star Ratings, highlighting a specific challenge Humana is addressing through its 'Stars program' initiatives aimed at achieving 'Top Quartile Stars results'.

Legal Proceedings

• Humana is involved in various legal actions or disputes that could lead to legal actions (e.g., provider contract disputes, qui tam litigation).
• Humana has filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through improved Adjusted EPS and revenue guidance, but also risks from declining GAAP EPS and Medicare Advantage Star Ratings impacting future payments.
• Customers (Members/Patients): Continued investment in improved outcomes, operational excellence, and a better experience, with strategic expansion of CenterWell and Medicaid services aimed at enhancing healthcare access and quality.
• Employees (Teammates): Commitment to putting health first for teammates, but also facing competition in attracting and retaining talented employees and managing succession for key executives.
• Providers: Focus on developing and maintaining satisfactory relationships with providers of care to members, with some provider-capitation accruals impacting claims payable.
• Regulatory Authorities: Subject to substantial government regulation, with changes in laws or regulations potentially increasing costs or restricting growth, and ongoing governmental audits and investigations.

Next Steps

• Continue investing in improved outcomes, operational excellence, and a better experience for customers and investors.
• Focus on achieving individual Medicare Advantage pretax margin of at least 3% over time.
• Continue efforts to strengthen the Stars program to achieve Top Quartile Stars results.
• Monitor PDP performance closely given the magnitude of IRA changes and potential impact on member behavior.
• Continue strategic expansion of CenterWell and Medicaid footprint, including the integration of the Virginia Medicaid contract.
• Improve Group MA margins through renewal cycles and re-contracting in 2026 and beyond.
• Execute on comprehensive initiatives to drive productivity and efficiency within the home operating model.
• Expand direct-to-consumer (DtC) programs in CenterWell Pharmacy through new partnerships.
• Maintain prudent near-term capital deployment approach due to expected Stars headwind in 2026.
• Continue efforts to increase balance sheet efficiency and fortify the foundation, including working capital improvements, asset sales, capital management, and prudent debt to capital management.

Key Dates

Recommendation

The filing presents a mixed financial picture. While Humana raised its Adjusted EPS and consolidated revenue guidance, indicating strong operational performance and strategic wins in key growth areas like CenterWell and Medicaid, it also lowered its GAAP EPS guidance. The ongoing challenge with Medicare Advantage Star Ratings for 2025, which will impact 2026 quality bonus payments, remains a significant headwind. The company is actively managing its MA portfolio by exiting unprofitable plans and showing improved recapture rates, and its balance sheet metrics are solid. However, the long-term implications of the Stars rating decline and the need for 'prudent' capital deployment suggest caution. A 'hold' recommendation is appropriate as the company navigates these complex dynamics, demonstrating resilience and strategic adaptation while facing notable challenges.

Keywords

Healthcare, Insurance, Medicare Advantage, Medicaid, CenterWell, Health Benefits, Financial Results, EPS Guidance, Revenue Guidance, Risk Adjustment, Pharmacy Benefit Manager, Value-Based Care, SEC Filing